Abstract:Immunotherapies has revolutionized the treatment approach of patients with metastatic cancer, although response rates to such therapies when given alone are disappointingly limited in the majority. Stereotactic ablative radiotherapy (SABR) increases immunogenic cell death, boosts priming of APCs, activates effector T-cell responses, and serves as an ideal partner of immunotherapy. Accounting for a large proportion of cells in the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs), along with their products such as fibroblast activation protein-α (FAPα), greatly affect tumor development and treatment resistance, which make them promising targets for immunotherapy. Therefore, the application of immunotherapy targeting CAFs combined with SABR may have a synergistic effect. We previously reported a xenogeneic FAPα-based whole cell tumor vaccine (WCTV) enhance specific antitumor responses to fight cancer cells and CAFs. This study aimed to test the efficacy and safety of SABR in combination with xenogeneic FAPα-based WCTV. In the present study, we firstly compare the different radiation schemes with a same biologically effective dose, the timing and sequence of the association of irradiation and FAPα-based WCTV in mouse LLC Lewis lung cancer model to investigate the optimal protocol. Mice were monitored for tumor growth, survival and gross measures of health. With the use of mouse H22 liver and 4T1 breast cancer models, we then tested the antitumor effect, safety and anti-fibrosis effect of the optimal combination protocol. The potential immune mechanisms were investigated through adoptive immunotherapy and 51Cr release assay. The distributions of the immune cells in the TME were detected by immunohistochemical staining and flow cytometry. SABR was dramatically more effective with 3x8Gy compared to 1×16.4Gy when associated with FAPα-based WCTV, and the best anti-tumor effect was observed in the group of mice started the vaccination on the 7th day after the last irradiation. No obvious side effects were detected following treatment. Tumor-infiltrating lymphocytes (TILs) ratio increased and products of CAF, such as FAPα, α-SMA and collagen I expression decreased in the tumor tissue. further investigation showed that the anti-tumor effect involves cellular and humoral immune responses. In the combination treatment group, T cells obtained from mice showed higher cytotoxicity against cancer cells and CAFs, and autoantibodies against FAPα were detected in the sera. These findings indicate combination of SABR and xenogeneic FAPα-based WCTV can weaken CAFs-mediated immune suppression, interstitial fibrosis and treatment tolerance to effectively inhabit tumor growth and reduce side effects. This study innovatively associates radiation therapy, anti-fibrosis therapy with immunotherapy, and provide new ideas for developing new treatment strategies for patients with multiple epithelial cancers.

Safe Engineering of Cancer-Associated Fibroblasts Enhances Checkpoint Blockade Immunotherapy.

Reprogramming of Cancer-Associated Fibroblasts Combined with Immune Checkpoint Inhibitors: A Potential Therapeutic Strategy for Cancers.

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Metabolic Reprogramming of Cancer‐Associated Fibroblasts: Transforming Tumor Accomplices into Immunotherapeutic Allies

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy to Enhance Cytotoxic T Cell Infiltration and Tumor Control

Targeting of Cancer-Associated Fibroblasts Enhances the Efficacy of Cancer Chemotherapy by Regulating the Tumor Microenvironment

Immunization of stromal cell targeting fibroblast activation protein providing immunotherapy to breast cancer mouse model

Synergistic Effect Of Stereotactic Ablative Radiotherapy And Immunotherapy With A Xenogeneic Fibroblast Activation Protein-Based Whole Cell Tumor Vaccine

Bioresponsive nanocomplex integrating cancer-associated fibroblast deactivation and immunogenic chemotherapy for rebuilding immune-excluded tumors

Metabolic Reprogramming by Dual-Targeting Biomimetic Nanoparticles for Enhanced Tumor Chemo-Immunotherapy

Dual-mechanism based CTLs infiltration enhancement initiated by Nano-sapper potentiates immunotherapy against immune-excluded tumors

Genetically Engineered Membrane-Based Nanoengagers for Immunotherapy of Pancreatic Cancer

Cancer-associated Fibroblast-Targeted Nanodrugs Reshape Colorectal Tumor Microenvironments to Suppress Tumor Proliferation, Metastasis and Improve Drug Penetration

Self-assembly nanomedicine initiating cancer-immunity cycle with cascade reactions for boosted immunotherapy

Reshaping Antitumor Immunity with Chemo‐Photothermal Integrated Nanoplatform to Augment Checkpoint Blockade‐Based Cancer Therapy

Targeting cancer-associated fibroblasts with hydroxyethyl starch nanomedicine boosts cancer therapy

Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy

Transformable Honeycomb-Like Nanoassemblies Of Carbon Dots For Regulated Multisite Delivery And Enhanced Antitumor Chemoimmunotherapy

Long-term combined blockade of CXCR4 and PD-L1 with in vivo reassembly for intensive tumor interference

Genetically Edited Cascade Nanozymes for Cancer Immunotherapy